Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
quadrivalent recombinant influenza vaccine (Sanofi Pasteur) (Sanofi)
- Development stage
- Unknown
- Lead developer
- Sanofi Pasteur
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This is an investigational quadrivalent recombinant influenza vaccine (RIV) developed by Sanofi Pasteur. Unlike traditional egg-based vaccines, it is produced using a baculovirus expression system to manufacture purified recombinant hemagglutinin (HA) proteins. This specific formulation is being evaluated in Phase 1 clinical trials to test different H3 hemagglutinin antigens and the inclusion of an adjuvant to enhance immunogenicity, particularly against drifted H3N2 strains. It is designed to provide protection against four influenza strains: two influenza A subtypes (H1N1 and H3N2) and two influenza B lineages (Victoria and Yamagata). The vaccine platform is related to the marketed Flublok Quadrivalent but represents a distinct investigational formulation with modified components.
- Other names
- Quadrivalent RIVRecombinant Influenza Vaccine Quadrivalent
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on quadrivalent recombinant influenza vaccine (Sanofi Pasteur) (Sanofi).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on quadrivalent recombinant influenza vaccine (Sanofi Pasteur) (Sanofi).